Cobalt Strikes Back At Pfizer In Lyrica Patent Spat

Law360, New York (May 20, 2009, 12:00 AM EDT) -- Cobalt Laboratories Inc. has hit back in Pfizer Inc.'s infringement suit over patents related to the nerve pain medication Lyrica, filing counterclaims seeking declaratory judgments of noninfringement and invalidity.

The generic-drug maker, along with its sister company Cobalt Pharmaceuticals Inc., filed the counterclaims Tuesday in the U.S. District Court for the District of Delaware.

Cobalt denies the allegations of infringement, argues that the complaint failed to state a claim upon which relief could be granted and says both the asserted patents were invalid for double patenting,...
To view the full article, register now.